Also in this playlist...
This transcript is automatically generated
All right Nicole thank you very much.
Biotech Celgene revealing new data on its popular drug problem that the American society and clinical oncology conference but I was asked -- In Chicago all bear doctor so bear some -- -- joins us now doctor -- to see you again good seeing thanks for joining us.
-- ask those really become a show I mean used to be you know in a few years ago more clinical and now everything is going on some market moving -- it's a big event.
Tell us about the data that you released of the com.
-- it was a great -- -- for us Brian is in rev limit our leading in ecological drove for but cancers we released really very exciting data.
Showing how -- prolongs the lives of patients.
With multiple myeloma a blood cancer both patients who just newly diagnosed.
Longer survival that has been seen so far in history would be -- -- newly diagnosed myeloma and in addition the patients who have believed he treated.
Without their drugs it is for years -- lasting and helping those patients so we're very excited about that data that was released.
For non hodgkin's lymphoma so our objective is to continue to develop -- when it.
As he therapy or -- over a variety of what -- sort of been their reaction for the medical community what about script trends except.
What's kind of early right -- -- -- officially ended.
Actually the other day but we're very excited the acceptance from the medical -- very positive.
A lot of great comments are that's go from physicians so we're really excited about this and the impact we can actually make them patients.
Like okay talk about Europe though because rebel that you withdrawn -- application from certain parts of the European regulatory scheme they won't they wanted to more data.
Correct right in where do you stand with -- In Europe.
We have approval from main indication we have launched in most of the countries in Europe that is going extremely well.
As expected we withdrew an application for a small indication that was his.
You know already in our projections no commercial impact for that.
Eight interest -- me that -- that application was accepted in Canada and in the United States but nevertheless that was as expected and we're proceeding.
In terms of trials in Europe the -- even -- and further the indication that we have as well as in Japan Australia and other countries.
And then that's it -- -- so many drugs in the market is the initial approval and -- increased indications how how big thing problem head and Salomon can mean.
-- -- at Salomon rev limit is now one of the most successful.
Let cancer drugs in history it has been on the market for.
Couple years or so it is doing very well as well if not better than any drug and history in that category.
In terms of revenues we think that this is going to be a blockbuster and it'll be successful could be sent Brian.
That it helps patients with serious debilitating illnesses and you've done something different recently made a deal.
Farming on you've got the drug the -- and has been some -- on that assaults Biotech and these are tough because it's such technical data.
In plain English put it what does the does -- do what are the benefits of it why why did you follow -- -- deal.
Did that says woods is a drug that is used for -- the ecological malignancy -- -- BS.
It is it is a very serious condition and -- Betsy is the first wrought in history.
That has shown an increase in survival for patients that have this fatal disease it is a very big deal army and did a great job in developing it.
We are selling it now with the United States a therapeutic product it is just -- -- -- it extends like that is the gold standard for any oncology product any cancer product.
It is very rare.
In this condition that this is the first time ever and we have an application for this.
In Europe right now for approval and hopefully we can start selling this next year in Europe so I -- when does this tip the balance.
Well it's -- -- hitting the balance sheet in the United States but the real impact I think -- going to come in Europe in 2009.
We're very excited.
Hard -- so bear Celgene we appreciate it doctor -- good to see again I was missing you all right I got some headlines -- -- don't want you here as well breaking news regarding Merck and Vioxx very quickly Fox Business alert.
New Jersey Supreme Court ruling that Vioxx users must first suffer an injury.
Before pursuing any claims Merck has been very successful and Vioxx lawsuits.
Now maybe the court a -- upholding.
A new standard very quick comment on that.
It's up very complicated but I think one of the dangers we have is.
It's the pharmaceutical companies are responsible for for everything bad that occurs hopefully that rationality will come back into the system.
Our -- so Barrett thank you very much so there you -- some headlines watch mark and mark -- -- difficult more more difficult living standard of causation in lawsuits now at least according to Merck and Vioxx and that lawsuit --
Filter by section